SEC Comment Letter for BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796) (BCRX) — Jan 25, 2011

BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796)
Date: Jan. 25, 2011 · CIK: 0000882796 · Accession: 0000000000-11-005037

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

January 25, 2011

Author

Jeffrey P. Riedler

Form

UPLOAD

Company

BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796)

Letter

Re: Biocryst Pharmaceuticals, Inc. Form 10- K for the year ended December 31, 2009 Filed March 9, 2010 Definitive Proxy Statement on Schedule 14A Filed April 6, 2010 File No. 000 -23186 Dear Mr. Stonehouse : We have completed our review of the above filing and have no further comments at this time.

January 25, 2011

Mr. Jon P. Stonehouse President and Chief Executive Officer Biocryst Pharmaceuticals, Inc. 2190 Parkway Lane Drive Birmingham, AL 35244

Sincerely,
Jeffrey P. Riedler
Assistant Director

Show Raw Text

January 25, 2011

Mr. Jon P. Stonehouse
President and Chief Executive Officer
Biocryst Pharmaceuticals, Inc.
2190 Parkway Lane Drive
Birmingham, AL  35244

Re: Biocryst Pharmaceuticals, Inc.
Form 10- K for the year ended December 31, 2009
Filed March 9, 2010 Definitive Proxy Statement on Schedule 14A
Filed April 6, 2010 File No. 000 -23186
 Dear Mr. Stonehouse :
 We have completed our review of the above filing and have no further comments  at this
time.

Sincerely,

  Jeffrey P. Riedler
Assistant Director

SecProbe.io